Spots Global Cancer Trial Database for Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
Official Title: An Intensive QT/QTc Study to Investigate the Effects of SGN-35 (Brentuximab Vedotin) on Cardiac Ventricular Repolarization in Patients With CD30-Positive Malignancies
Study ID: NCT01026233
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate cardiac safety of brentuximab vedotin (SGN-35) in patients with CD30-positive cancers. The study will assess electrical activity of the heart before and after brentuximab vedotin administration. Patients who have stable or improving disease may receive up to 1 year of brentuximab vedotin treatment.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
City of Hope National Medical Center, Duarte, California, United States
Stanford Cancer Center, Stanford, California, United States
University of Miami Hospital and Clinics, Miller School of Medicine, Miami, Florida, United States
Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States
New York University Cancer Institute, New York, New York, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Baylor University Medical Center, Dallas, Texas, United States
University Hospital of Cologne, Koln, , Germany
Contact Details
Name: Naomi Hunder, MD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
